[go: up one dir, main page]

CA2360124A1 - Regulation d'anesthesie - Google Patents

Regulation d'anesthesie Download PDF

Info

Publication number
CA2360124A1
CA2360124A1 CA002360124A CA2360124A CA2360124A1 CA 2360124 A1 CA2360124 A1 CA 2360124A1 CA 002360124 A CA002360124 A CA 002360124A CA 2360124 A CA2360124 A CA 2360124A CA 2360124 A1 CA2360124 A1 CA 2360124A1
Authority
CA
Canada
Prior art keywords
dsip
anaesthesia
anaesthetic
activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002360124A
Other languages
English (en)
Inventor
Christopher John Douglas Pomfrett
Michael Alkire
Richard Haier
Jim Fallon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902469.7A external-priority patent/GB9902469D0/en
Application filed by Individual filed Critical Individual
Publication of CA2360124A1 publication Critical patent/CA2360124A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation de composés qui modulent l'activité du peptide inducteur de sommeil delta (DSIP), destinés à réguler l'anesthésie, ainsi que des méthodes d'évaluation des besoins anesthésiques d'un sujet comprenant un test de présence de DSIP dans un échantillon prélevé sur un sujet.
CA002360124A 1999-02-05 2000-02-01 Regulation d'anesthesie Abandoned CA2360124A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9902469.7 1999-02-05
GBGB9902469.7A GB9902469D0 (en) 1999-02-05 1999-02-05 Brain metabolism
US12032699P 1999-02-17 1999-02-17
US60/120,326 1999-02-17
US15566199P 1999-09-24 1999-09-24
US60/155,661 1999-09-24
PCT/GB2000/000281 WO2000045832A2 (fr) 1999-02-05 2000-02-01 Regulation d'anesthesie

Publications (1)

Publication Number Publication Date
CA2360124A1 true CA2360124A1 (fr) 2000-08-10

Family

ID=27269636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360124A Abandoned CA2360124A1 (fr) 1999-02-05 2000-02-01 Regulation d'anesthesie

Country Status (15)

Country Link
EP (1) EP1148887A2 (fr)
JP (1) JP2002536337A (fr)
KR (1) KR20010101992A (fr)
CN (1) CN1346278A (fr)
AP (1) AP2001002245A0 (fr)
AU (1) AU2445900A (fr)
BR (1) BR0008046A (fr)
CA (1) CA2360124A1 (fr)
ID (1) ID30518A (fr)
IL (1) IL144572A0 (fr)
MX (1) MXPA01007949A (fr)
NO (1) NO20013795D0 (fr)
OA (1) OA11758A (fr)
TR (1) TR200102265T2 (fr)
WO (1) WO2000045832A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275308A1 (fr) * 2001-07-13 2003-01-15 The Procter & Gamble Company Composition alimentaire ayant des propriétés relaxantes pour les mammifères
US20100210540A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
GB201116271D0 (en) * 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
CN108376559B (zh) * 2018-02-28 2020-10-16 复旦大学附属中山医院 乙醛脱氢酶2基因型在麻醉剂量计算中的应用
CN112535727A (zh) * 2020-12-24 2021-03-23 安域生物制药(杭州)有限公司 一种具有睡眠改善作用的短肽凝胶及其制备方法
CN112908454B (zh) * 2021-02-26 2023-08-29 西安交通大学口腔医院 一种智能保管麻醉剂的方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH634331A5 (de) * 1977-06-30 1983-01-31 Hoffmann La Roche Phosphorylierte nonapeptide und verfahren zu deren herstellung.
CA1188989A (fr) * 1981-05-21 1985-06-18 Richard R. Scherschlicht Nonapeptide pour le traitement des symptomes du sevrage
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
RU2104717C1 (ru) * 1995-07-07 1998-02-20 Новокузнецкий государственный институт усовершенствования врачей Способ анестезии при операциях у больных с синдромом лериша

Also Published As

Publication number Publication date
AP2001002245A0 (en) 2001-09-30
TR200102265T2 (tr) 2001-12-21
WO2000045832A3 (fr) 2000-11-30
OA11758A (en) 2005-07-19
AU2445900A (en) 2000-08-25
ID30518A (id) 2001-12-13
EP1148887A2 (fr) 2001-10-31
MXPA01007949A (es) 2003-06-04
JP2002536337A (ja) 2002-10-29
WO2000045832A2 (fr) 2000-08-10
NO20013795L (no) 2001-08-02
NO20013795D0 (no) 2001-08-02
IL144572A0 (en) 2002-05-23
KR20010101992A (ko) 2001-11-15
BR0008046A (pt) 2001-11-06
CN1346278A (zh) 2002-04-24

Similar Documents

Publication Publication Date Title
US6562855B1 (en) Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist
CN102686221B (zh) 治疗疼痛的方法
JP2003529541A6 (ja) ＮＭＤＡ拮抗薬とα２アドレナリン作用薬とを含む麻酔製剤
US5432176A (en) Method of retarding the progression of chronic renal failure
Cunningham et al. Dissociation of experimentally induced drinking behavior by ibotenate injection into the median preoptic nucleus
Grutzner et al. Effect of injury on pulpal levels of immunoreactive substance P and immunoreactive calcitonin gene-related peptide
Tarbeeh et al. Effects of intrathecal bupivacaine–fentanyl versus bupivacaine–dexmedetomidine in diabetic surgical patients
CA2360124A1 (fr) Regulation d'anesthesie
US6437093B1 (en) Methods of treatment comprising administration of Substance P
ZA200106256B (en) Regulation of anaesthesia.
Collin et al. Feedback inhibition of met‐enkephalin release from the rat spinal cord in vivo
Mitchell et al. The long-term effect of epidural administration of butamben suspension on nerve injury-induced allodynia in rats
McCleane Cholecystokinin and its antagonists in pain management
AU2001296493B2 (en) Use of neuropeptide-Y antagonists in treatment of alcoholism
Van Dijk et al. Changes in heart rate, mean arterial pressure, blood biochemistry, plasma glucose, plasma lactate and some plasma enzymes during sufentanil/halothane anaesthesia in horses
Salmasi et al. Influence of adenosine and ADP on expression of surface antigens of human T-lymphocytes is connected with stimulation of single type of purine receptors
Popoli et al. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease
Burns et al. Ultra-low-dose naltrexone decreases dependence and addictive properties of opioids
Maldonado et al. Treatment of Opiate Withdrawal
Chaiyakul Interactive effects of lidocaine and dextromethorphan in animal analgesia models
Kang Neurochemical and Behavioural Changes Foiiowing Propofol Anesthesia in the Rat.
Guindon et al. The antinociceptive effects of local injections of propofol are mediated by cannabinoid CB1 and CB2 receptors: A-599
Strumper et al. Amitriptyline and fluoxetine inhibit human NMDA receptor signaling: A-783
HK1176287A (en) Methods for treatment of pain
AU2001296493A1 (en) Use of neuropeptide-Y antagonists in treatment of alcoholism

Legal Events

Date Code Title Description
FZDE Discontinued